文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

CYP2D6 表型对阿立哌唑代谢异常影响的回顾性队列研究

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.
PubMed 文献 · Am J Health Syst Pharm · 2026-01-01

该回顾性队列研究纳入 1,562 例接受阿立哌唑口服处方且具有 CYP2D6 基因分型的患者,比较不同表型组代谢指标变化。多变量混合效应分析显示基因型表型组间无显著差异,仅弱代谢者与正常代谢者甘油三酯变化呈边缘性差异(β=23.42,范围 -4.9 至 51.73,P=0.11)。结论提示 CYP2D6 弱代谢者除 LDL 外代谢异常发生率可能不高于正常代谢者。

要点

  • CYP2D6 基因型表型组间代谢指标变化无显著差异。
  • 弱代谢者与正常代谢者甘油三酯变化呈边缘性差异(P=0.11)。
  • 纳入表型转换后弱代谢者 LDL 平均变化升高且差异有统计学意义。

核心结论

  • CYP2D6 弱代谢者除 LDL 外代谢异常发生率可能不高于正常代谢者。
  • 尚需进一步研究探讨 CYP2D6 与阿立哌唑相关的临床有意义结局。

研究设计与样本

  • 回顾性队列研究,纳入具有 CYP2D6 基因分型且口服阿立哌唑处方的患者。
  • 共分析 1,562 例患者,采用多变量混合效应分析。
  • 合并使用 CYP2D6 抑制药物者归类为表型转换者,亚分析中归为弱代谢者。

主要发现

  • 基因型表型队列各代谢指标变化无显著差异。
  • 弱代谢者与正常代谢者甘油三酯水平呈边缘性差异(β=23.42;范围 -4.9 至 51.73;P=0.11)。
  • 纳入表型转换后,弱代谢者 LDL 平均变化升高(β=10.04;范围 1.46 至 18.61;P<0.05)。
  • 纳入表型转换后,弱代谢者 BMI 平均变化降低(β=-0.34;范围 -0.72 至 0.04;P=0.08),但差异无统计学意义。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate the influence of CYP2D6 functionality on metabolic abnormalities in patients prescribed aripiprazole. METHODS: A retrospective cohort review was conducted in patients who had CYP2D6 genotyping and an oral prescription for aripiprazole. Primary outcomes were changes in metabolic parameters from baseline based on CYP2D6 genotype-based phenotype. Patients concurrently taking medications that cause CYP2D6 inhibition were classified as phenoconverters and were categorized as poor metabolizers in subanalyses. Index and post-aripiprazole (after either initiation or dose modification) data were abstracted from the electronic medical record for the following endpoints: body mass index (BMI), blood glucose, glycated hemoglobin, low-density lipoprotein (LDL), triglycerides, and total cholesterol. RESULTS: In multivariate mixed-effects analysis of 1,562 patients, the genotype-based phenotype cohort had no significant differences. A marginal difference in triglyceride levels was observed between poor metabolizers and normal metabolizers (β = 23.42; range, -4.9 to 51.73; P = 0.11). Findings were similar between poor metabolizers and normal metabolizers when evaluating outcomes encompassing phenoconversion, although poor metabolizers had an increased mean change in LDL levels (β = 10.04; range, 1.46 to 18.61; P < 0.05) and had a decreased mean change in BMI (β = -0.34; range, -0.72 to 0.04; P = 0.08); however, these differences were not statistically significant. CONCLUSION: This study suggests that the incidence of metabolic abnormalities beyond LDL may not be higher in CYP2D6 poor metabolizers compared to normal metabolizers. Further research is needed to investigate clinically meaningful outcomes in relation to CYP2D6 and aripiprazole.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Meissner BR, Younes F, Massmann A, et al. Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities. Am J Health Syst Pharm. 2026. PMID: 41364071. doi:10.1093/ajhp/zxaf345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。